Sunovion Pharmaceuticals Inc.has entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to three approved medicines, Utibron Neohaler inhalation powder, Seebri Neohaler inhalation powder and Arcapta Neohaler, which are indicated for the long-term, maintenance of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). The agreement expands Sunovion’s COPD portfolio in the U.S., providing handheld and nebulized treatment options for all stages of COPD.
 
Sunovion has the exclusive rights to market the products in the U.S. Utibron Neohaler and Seebri Neohaler were approved by the FDA in 2015, and Sunovion plans to bring them to market in 2017. Arcapta Neohalerwas approved in the U.S. in 2011 and made available in 2012. Novartis will continue to manufacture these three medicines under the terms of the agreement. Novartis and its affiliates will continue to retain the commercialization rights for Ultibro Breezhaler, Seebri Breezhalerand Onbrez Breezhaler outside of the U.S.
 
“Sunovion has a long-standing commitment to advancing respiratory health and to providing new treatment options for people with COPD,” said David Frawley, executive vice president and chief commercial officer, Sunovion. “We are pleased to add Utibron Neohaler, Seebri Neohaler and ArcaptaNeohaler to our respiratory portfolio as these will complement our existing products and allow us to provide a wide range of treatment options for people with COPD.”